At 18 months , the mortality rate was 11.9 / 100 person-years ( py ; 95 % CI 1.4-42 .8 ) in the combined integrated treatment arm and 56.0 / 100 py ( 95 % CI 18.2-130 .8 ) in the sequential treatment arm ( hazard ratio adjusted for baseline CD4 count and whether MDR-TB treatment was initiated : 0.14 ; 95 % CI 0.02-0 .94 , P = 0.04 ) .